|
Bare Lymphocyte Syndrome, Type I
|
0.610 |
Biomarker
|
disease |
BEFREE |
These results suggest that tapasin deficiency is another cause of type I BLS.
|
12149238 |
2002 |
|
Bare Lymphocyte Syndrome, Type I
|
0.610 |
GermlineCausalMutation
|
disease |
ORPHANET |
A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to deletion of 4 exons by Alu-mediated recombination.
|
12149238 |
2002 |
|
Bare Lymphocyte Syndrome, Type I
|
0.610 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to deletion of 4 exons by Alu-mediated recombination.
|
12149238 |
2002 |
|
Bare Lymphocyte Syndrome, Type I
|
0.610 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
We found significant associations between schizophrenia and TAP1 allele frequencies (P=9.95x10(-3), chi(2)=12.36) as well as TAPASIN allele frequencies (P=2.8x10(-2), chi(2)=5.3).
|
19217216 |
2009 |
|
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We found significant associations between schizophrenia and TAP1 allele frequencies (P=9.95x10(-3), chi(2)=12.36) as well as TAPASIN allele frequencies (P=2.8x10(-2), chi(2)=5.3).
|
19217216 |
2009 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis.
|
21156761 |
2011 |
|
Bronchiectasis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Bronchiolitis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Ectopia Lentis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Nasal Polyps
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Chronic sinusitis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Chronic otitis media
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Recurrent bronchitis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Hepatitis C
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Tapasin alleles contribute to the outcome of HCV infection by synergizing with polymorphisms at HLA-B in a population-specific manner.
|
23532923 |
2013 |
|
Hepatitis C
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Our study implicated that TAP2, HLA-DOA, HLA-DOB, and tapasin loci were novel candidate regions for susceptibility to HCV infection and viral clearance in the Chinese population.
|
25874709 |
2015 |
|
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
The current study determined the genotypes of 34 tagging-SNPs (single nucleotide polymorphisms) from 9 candidate genes (HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, TAP1, TAP2, LMP2, LMP7, and tapasin) in a Chinese population of paid blood donors with high risk of HCV infection.
|
25528575 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we assessed tapasin expression in 85 primary tumor lesions of non-small cell lung cancer (NSCLC) patients, demonstrating that tapasin expression positively correlated with patient survival.
|
28344889 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The present study examines the expression of HLA, tapasin, transporter associated with antigen processing 1 (TAP1), and beta2 microglobulin in human small cell lung carcinoma and non-small cell lung carcinoma.
|
16140964 |
2005 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Consistent with published functional data showing that tapasin promotes antigen presentation, as well as tumor immune recognition and destruction by CD8(+) CTLs, a reduction in tapasin expression is associated with tumor progression in CRC.
|
26310568 |
2015 |
|
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Finally, we determined that rs3106189, localized to the 5' UTR of antigen presenting tapasin binding protein (TAPBP), and rs1052918, localized to the 3' UTR of transcription factor 3 (TCF3), were associated with overall survival of CRC patients.
|
23940558 |
2013 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
To compare the effectiveness (metabolic control) and safety of two insulin regimens in patients with diabetes receiving TPN.
|
30930133 |
2020 |
|
Diabetes
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The following characteristics were significantly associated with severe CKD: female gender (HR 1.34), older age (HR 1.38/10 year increment), catheter-related sepsis (HR 1.58), steroid maintenance immunosuppression (HR 1.50), graft failure (HR 1.76), ACR (HR 1.64), prolonged requirement for IV fluids (HR 2.12) or TPN (HR 1.94), and diabetes (HR 1.54).
|
28241392 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Prospective, open-label, multicenter, clinical trial on adult inpatients with type 2 diabetes on a non-critical setting with indication for TPN.
|
30930133 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
BG = blood glucose; CG = conventional glycemic control; ENT = enteral nutrition therapy; GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide 1; IG = intensive glycemic control; IV = intravenous; NPH = neutral protamine Hagedorn; PNT = parenteral nutrition therapy; SQ = subcutaneous; T2DM = type 2 diabetes mellitus; TDD = total daily dose; TPN = total parenteral nutrition.
|
30035626 |
2018 |